Evidence map›Paper›PMID 31988098›Full record

ArticleAntimicrobial agents and chemotherapy2020

Jemila C Kester, Douglas K Brubaker, Jason Velazquez, Charles Wright, Douglas A Lauffenburger, Linda G Griffith

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.2field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Jemila C KesterDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.ORCID 0000-0001-8639-284X
Douglas K BrubakerDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
Jason VelazquezDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
Charles WrightDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
Douglas A LauffenburgerDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
Linda G GriffithDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA griff@mit.edu.
Massachusetts Institute of Technology · US

Funding

TOXICOLOGY CORE UNITP30ES002109 · NIEHS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI LEVINE, STUART S · 1985 to 2020
$25.6M
GuMI: New In Vitro Platforms to Parse the Human Gut Epithelial-Microbiome-Immune AxisR01EB021908 · NIBIB · NORTHEASTERN UNIVERSITY · PI CARRIER, REBECCA L, GRIFFITH, LINDA G · 2016 to 2020
$5.2M
NIBIB NIH HHS R01 EB021908NIEHS NIH HHS P30 ES002109
6 · The paper itself

Abstract

A clinically relevant risk factor for

Indexed as

Anti-Bacterial AgentsCaco-2 CellsCell Line, TumorCiprofloxacinClindamycinClostridioides difficileEnterocolitis, PseudomembranousGastrointestinal MicrobiomeHT29 CellsHumansMucous MembraneRisk FactorsTigecyclineTight JunctionsAnti-Bacterial AgentsCiprofloxacinClindamycinTigecyclineClostridioides difficileenteric organoid/enteroidgerm freehost responsepostantibiotic effectsystems biology

Identifiers

PMID31988098
PMCPMC7179307
OpenAlexW3002712534

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.